000047562 000__ 01041nam\a2200409\i\4500
000047562 001__ 47562
000047562 003__ SzGeWIPO
000047562 005__ 20230503170059.0
000047562 006__ m\\\\eo\\d\\\\\\\\
000047562 007__ cr bn |||m|||a
000047562 008__ 230320s2022\\\\enk\\\\\o\\\\\000\0\eng\d
000047562 0247_ $$a10.1093/jiplp/jpac097$$2doi
000047562 035__ $$a(OCoLC)1373643120
000047562 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000047562 041__ $$aeng
000047562 24500 $$aCOVID-19 vaccines, patents and an IP waiver.
000047562 264_1 $$a[Oxford, England] :$$bOxford University Press (OUP),$$c2022
000047562 300__ $$a1 online resource (pages 940-945)
000047562 336__ $$atext$$2rdacontent
000047562 337__ $$acomputer$$2rdamedia
000047562 338__ $$aonline resource$$bcr$$2rdacarrier
000047562 4901_ $$aJournal Of Intellectual Property Law & Practice,$$x1747-1540 ;$$v17, 11, 2022
000047562 542__ $$fhttps://academic.oup.com/jiplp/article-abstract/17/11/940/6845521
000047562 588__ $$aCrossref
000047562 590__ $$aPublished online: 24-Nov-22
000047562 650_4 $$aIntellectual Property Rights.
000047562 650_4 $$aCovid-19.
000047562 650_0 $$aPatents.
000047562 650_0 $$aIntellectual property.
000047562 650_0 $$aCOVID-19 (Disease)
000047562 7001_ $$aAerts, Rob J.,$$eauthor.
000047562 7731_ $$tJournal of Intellectual Property Law & Practice$$wjiplp
000047562 830_0 $$aJournal Of Intellectual Property Law & Practice ;$$v17, 11, 2022.
000047562 85641 $$uhttps://doi.org/10.1093/jiplp/jpac097$$yOnline version
000047562 904__ $$aArticle
000047562 980__ $$aJIPLP